Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
GPCR Stock Chart & Stats
$36.82
-$0.32(-1.18%)
At close: 4:00 PM EST
$36.82
-$0.32(-1.18%)
Day’s Range― - ―
52-Week Range$13.22 - $37.76
Previous CloseN/A
Volume219.80K
Average Volume (3M)906.74K
Market Cap
$2.18B
Enterprise Value$845.76M
Total Cash (Recent Filing)$799.04M
Total Debt (Recent Filing)$7.09M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding60,677,640
10 Day Avg. Volume891,974
30 Day Avg. Volume906,737
Financial Highlights & Ratios
PEG Ratio3.15
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-12.11
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.23K
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$69.57Price Target Upside88.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.39
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Competitive Position In Obesity TreatmentThe completion of enrollment in the ACCESS I and ACCESS II Phase 2b studies for aleniglipron, an oral small molecule GLP-1R agonist, enhances Structure's competitive position in the obesity treatment field.
Financial HealthStructure remains well-capitalized with $836.9M in cash, cash equivalents, and short-term investments, indicating strong financial health to support ongoing research and development.
Phase 3 Candidate PotentialStructure is approaching a pivotal inflection point with expected data that could validate aleniglipron as a Phase 3 candidate.
Bears Say
Insurance And Cost BarriersInsurance coverage and cost of therapy is a primary barrier to treatment for patients.
Market Reaction RiskRecent obesity data for a similar drug, orfoglipron, received poorly by investors, highlighting the risk of market reactions to clinical trial outcomes.
Participant Retention ChallengesApproximately 25% of participants discontinued the study for any reason across all arms, indicating some challenges with participant retention.
Structure Therapeutics, Inc. Sponsored ADR News
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $13.22 and its highest was $37.76 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $2.18B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Mar 26, 2026 which is in 131 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Nov 06, 2025. The company reported -$1.125 earnings per share for the quarter, missing the consensus estimate of -$0.375 by -$0.75.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 60,677,640 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$1.125 in its last earnings report, missing expectations of -$0.375. Following the earnings report the stock price went down -1.882%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$69.57 (88.95% Upside)
$69.57 (88.95% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 49.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.76%
12-Months-Change
Fundamentals
Return on Equity
-25.31%
Trailing 12-Months
Asset Growth
-10.83%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
GPCR Stock 12 Month Forecast
Average Price Target
$69.57
▲(88.95% Upside)
Technical Analysis
Ownership Overview
11.29% Insiders
23.45% Mutual Funds
48.75% Other Institutional Investors
15.48% Public Companies and Individual Investors